Progenitor Cell Therapy Announces Collaboration With BD To Co-Develop And Market Assays For The Growing Cell Therapy Industry

Published: Nov 17, 2005

HACKENSACK, New Jersey -(November 17, 2005) -- Progenitor Cell Therapy, LLC (PCT), a leading cell therapy manufacturing and services company, today announced an agreement with BD Biosciences, a segment of Becton, Dickinson and Company (BD), to co-develop and market products and services for the cell therapy industry, including: product characterization and comparability assays; in-process and final product release tests; and PCT’s contract cell therapy development and manufacturing platform resources.

Back to news